**Question:** Which of the following tumor is associated with BRAF mutation?

A. Melanoma
B. Colorectal cancer
C. Non-small cell lung cancer
D. Papillary thyroid cancer

**Core Concept:** BRAF mutations are genetic alterations that occur in certain types of cancer, affecting the RAS-RAF-MEK-ERK signaling pathway. This pathway is essential for regulating cell growth, differentiation, and survival.

**Why the Correct Answer is Right:** BRAF mutations are primarily associated with D599V and V600E point mutations in the BRAF gene. The V600E mutation is particularly common and leads to constitutive activation of the RAS-RAF-MEK-ERK pathway, promoting uncontrolled cell growth and survival.

**Why Each Wrong Option is Incorrect:**

A. Melanoma: While BRAF mutations are present in around 50% of melanomas, not all melanomas are associated with BRAF mutations. Other genetic alterations, such as NRAS mutations or BRAF wild-type, can also cause melanoma.

B. Colorectal cancer: While BRAF mutations are less common in colorectal cancer (around 5-10%), they are still present in some cases. However, the most common mutations in colorectal cancer are KRAS and NRAS mutations and BRAF wild-type status.

C. Non-small cell lung cancer: BRAF mutations are relatively rare in non-small cell lung cancer, occurring in less than 5% of cases. The most common mutations in this cancer type are EGFR and ALK mutations, as well as wild-type status.

D. Papillary thyroid cancer: BRAF mutations are found in approximately 20-50% of papillary thyroid cancers. The most common mutations include RET and RAS mutations, as well as BRAF wild-type status.

**Clinical Pearl:** Understanding the association between BRAF mutations and specific tumor types is crucial for targeted therapy approaches. For example, the BRAF inhibitor vemurafenib is approved for the treatment of BRAF V600E mutation-positive melanoma and papillary thyroid cancer.

**Correct Answer:** D. Papillary thyroid cancer

**Why D is Right:** Papillary thyroid cancer is the most likely option associated with BRAF mutations, specifically the V600E mutation. BRAF V600E mutations are found in approximately 20-50% of papillary thyroid cancers, which makes it the correct answer. Other thyroid cancer types, such as follicular thyroid cancer, may have different driver mutations, like RAS or RET mutations, or may be BRAF wild-type.